HS-10383
Phase 2Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-10383 is one of 31 small molecule programs targeting Chronic Cough. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Chronic Cough
#DrugCompanyPhaseTrials
1Singulair
OOrganon and Co
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Nucala
GGlaxo Dba Glaxosmithkline
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Quietus
Merck & Co.Phase 2
Prilosec
DDexcel Pharma Technologies Ltd.
Phase 3
Indocin
LLife Extension Foundation Inc.
Phase 3
Elavil
AstraZenecaPhase 2
Cymbalta
Alnylam PharmaceuticalsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Cough1 trial
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-10383. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details